Insys Ch. 11 Sale Of Controversial Drug OK'd With New Limits

By Vince Sullivan · September 19, 2019, 1:08 PM EDT

Insys Therapeutics Inc. received bankruptcy court approval Thursday in Delaware for a sale of its controversial pain medication Subsys after the buyer agreed to limit its marketing and distribution efforts to...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Insys Therapeutics, Inc.

Case Number

Court

Delaware

Nature of Suit

Date Filed

June 10, 2019

Recent Articles By Vince

June 10, 2024
Ventilator Co. Vyaire Hits Ch. 11 As COVID Demand Wanes
May 17, 2024
Healthcare Co. Sues Steward In Ch. 11 Over Military Contract
March 12, 2024
Breast Implant Co.'s $90M DIP OK'd With Creditor Protections
March 04, 2024
Hospital Operator Pushes For Ch. 11 Plan Confirmation
February 06, 2024
Cano Health DIP Gets Initial OK Without $23M Lender Fees
January 22, 2024
Skin Care Drug Co. Timber Gets OK For Ch. 11 Sale To Lender
January 10, 2024
US Trustee Calls SmileDirect Ch. 11 Deal An Improper Plan
December 06, 2023
GenesisCare Gets OK For $20M DIP Funding Hike
December 01, 2023
Alecto Health Can Continue With Subchapter V Designation
November 29, 2023
Alecto Health Co. Says Threshold Met For Subchapter V Status